Trials / Terminated
TerminatedNCT00728091
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH. Secondary objectives are to assess the safety of satavaptan, the maintenance of effect, and the clinical benefit in these participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Satavaptan | tablets |
| DRUG | placebo | tablets |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-08-05
- Last updated
- 2016-05-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00728091. Inclusion in this directory is not an endorsement.